The new data – from the ARISE trial – found that Cobenfy wasn't statistically better than placebo at improving the widely ...

Cobenfy’s late-stage flop is BMS’ second high-profile failure in as many weeks. The pharma announced last week that Camzyos ...

US pharma major Bristol Myers Squibb (NYSE: BMY) saw its shares fall 4% in after-hours trading on Tuesday, after it announced ...

In the Phase III ARISE trial, Cobenfy administered as an adjunctive treatment to atypical antipsychotics for patients with ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...

The therapy showed a two-point reduction in total PANSS score at week six against placebo with atypical antipsychotic.

Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics demonstrated a 2.0-point ...

Bristol Myers Squibb & Co (NYSE:BMY) on Tuesday released topline results from the Phase 3 ARISE trial evaluating the efficacy ...

In the phase III ARISE trial, adjunctive xanomeline and trospium chloride (Cobenfy) were no better than placebo at improving ...

The new schizophrenia drug didn’t provide additional benefits when given on top of standard-of-care therapy, Bristol Myers ...

Jefferies analyst Akash Tewari lowered the firm’s price target on Bristol Myers (BMY) to $68 from $70 and keeps a Buy rating on the shares ...

Shares of Bristol Myers Squibb (BMY) fell more than 4% after the closing bell on Tuesday after the biopharma company reported ...